Clinical Trial

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.

The 2nd annual Chicago River Swim celebrates the river's historic cleanup, raises funds for ALS research, and promotes youth water safety in a new civic event.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new study validates Noah Medical's robotic bronchoscopy, showing near-perfect accuracy in diagnosing hard-to-reach lung nodules.

With a key clinical trial complete, Emboline's new funding aims to commercialize a device designed to make popular heart procedures safer for patients.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.

A new analysis shows AI platforms can cut hospital costs by $2M annually while reducing ICU stays and ventilation time, transforming critical care.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

A new drug targeting the root cause of deadly device infections enters a pivotal trial, offering hope to millions and challenging a $20 billion problem.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Promising clinical trial results for Insulet's fully closed-loop system aim to revolutionize daily management for millions with Type 2 diabetes.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

Emalex Biosciences offers its investigational drug ecopipam to Tourette syndrome patients out of options, signaling a potential shift in treatment.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.